Faculty

Institution

Unit

Venue

Eric Jonasch

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Clinical Cancer Genetics

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

Eric Jonasch is a Senior Professor at The University of Texas MD Anderson Cancer Center, specializing in oncology and urology. His research focuses on kidney cancer, particularly von Hippel-Lindau disease-associated renal cell carcinoma, oligometastatic clear-cell renal cell carcinoma, and non-clear cell variant histology. His recent work includes the LITESPARK-004 phase 2 trial of belzutifan, published in The Lancet Oncology, and studies on nivolumab plus ipilimumab and lenvatinib plus everolimus versus cabozantinib. He has received major grants, including the Kidney Cancer Clinical Trials Consortium award (2018) and research on prognostic markers of immunogenicity in renal cell carcinoma (2017).

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Eric Jonasch

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology urology kidney cancer genitourinary cancers cancer care cancer treatment cancer research medicine metastasis pharmacology surgical oncology medicinal research nephrology radiation oncology pharmacotherapy tumor biology renal cell carcinoma oncogenes cancer immunotherapy cancer cells kidney research cancer biology molecular cancer cancer management cellular therapy therapeutic targets jama oncology cancer discovery anti-cancer agents immune checkpoint inhibitors vascular biology cancer genomics surgical pathology cancer genetics tumor targeting thoracic oncology leukemia therapeutic efficacy von hippel-lindau disease phase ii study cancer risk brain tumor research cohort studies cancer immunosurveillance tumor suppressors cytoreductive nephrectomy randomized controlled trials cancer growth prognosis sarcomatoid dedifferentiation gynecologic oncology treatment and prevention renal function von hippel-lindau gastrointestinal oncology clinical mycology hematological malignancies renal pathophysiology renal care united states clinical evidence melanoma phase ii trial targeted therapies renal medullary carcinoma tumoral pathology malignant disease prognostic biomarkers targeted therapy cell regulation systemic therapy comparative effectiveness retrospective chart review tyrosine kinase inhibitors dose titration pilot trial

Notable Scholarly Works

Notable Federal Grants

Collaborators

Monitoring and Treatment Patterns of Von Hippel-Lindau Disease-Associated Central Nervous System Hemangioblastomas. Hereditary Cancer in Clinical Practice (2026)

neurologymedicineanatomical pathologyneuropathologytreatment patternspathology

1057 Early Targeted Biologics Are Associated With Improved Clinical Outcomes in Immune-Related Myocarditis, Myositis, and Myasthenia Gravis. Regular and Young Investigator Award Abstracts (2025)

immunologymedicineinflammatory diseasesimmune-related myocarditisautoimmune diseasesimmunologic diseasesimproved clinical outcomesrheumatismmyositisimmune responsesclinical rheumatologyautoimmunitymyasthenia gravisimmunotherapyinflammation

2596Mo Phase Ib/II Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2A Receptor Antagonist) in First-Line Advanced Renal Cell Carcinoma (Rcc), a Kidney Cancer Research Consortium Study. Annals of Oncology (2025)

kidney researchpharmacologynephrologymolecular cancerurologypharmacotherapygenitourinary cancersoncologykidney cancermedicinal researchcancer treatmentphase ib/ii trial

48Immunotherapy Response Correlates in Metastatic Clear Cell Renal Cell Carcinoma From Circulating Cell-Free Epigenomes. The Oncologist (2025)

immunologyresponse correlatescell-free epigenomesmetastasiscancer immunosurveillanceurologycancer discoverycancer immunotherapygenitourinary cancerskidney cancercancer cellsimmunotherapy

Abstract Ct132: Phase 2 Trial of Metastasis Directed Radiotherapy Without Systemic Therapy (Mrws) for Oligometastatic Clear Cell Renal Cell Carcinoma (Ccrcc) and Investigation of Circulating Tumor Dna (Ctdna) as a Personalized Biomarker. Cancer Research (2025)

metastasisradiation oncologysurgical oncologyurologygenitourinary cancerscancer imagingphase 2oncologykidney cancerabstract ct132cancer treatmentjama oncologypersonalized biomarker

A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned From Other Cancer Types. European Urology (2025)

Axel BexMichael JewettBryan LewisE Jason AbelLaurence AlbigesStephanie A BergGennady BratslavskyDavid BraunJames BrugarolasToni K ChoueiriAntonio FinelliDaniel GeorgeNaomi B HaasA Ari HakimiHans HammersMichelle HirschEric JonaschPayal KapurW Marston LinehanViraj MasterBradley McGregorRana R McKayRohit MehraSumantha PalSusan PoteatThomas B PowlesSabrina H RossiDaniel D ShapiroSabina SignorettiEric A SingerChuck StravinNizar TannirUlka VaishampayanWenxin XuGrant D Stewart

kidney researchother cancer typescancer carenephrologyurologyoncologykidney cancerrenal care

A Multicenter Randomized Phase II Trial of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Clear-Cell Rcc That Progressed on Pd-1 Immune Checkpoint Inhibition (Lencabo). Annals of Oncology (2025)

metastasismetastatic clear-cell rccmedicinecancer immunosurveillanceeverolimus versus cabozantinibimmune checkpoint inhibitorstherapeutic targetscancer immunotherapyphase ii trialcancer treatmentimmunotherapyimmunologypharmacologypharmacotherapyoncologycancer cellsmedicinal researchcellular therapyexperimental medicine

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (Boost-Rcc).. Journal of Clinical Oncology (2025)

Tian ZhangQian QinSuzanne ColeAndrew Zhuang WangPavlos MsaouelAndrew Warren HahnAmishi Yogesh ShahMatthew T. CampbellSong ZhangRebecca Slack TidwellWadih IssaAndrew DeVilbissChangchuan JiangJoseph VentoKevin Dale CourtneyHans J. HammersJames BrugarolasNizar M. TannirEric Jonasch

phase ii studykidney cancergastrointestinal oncologytumor targetinganti-cancer agentscancer researchurologycancer immunotherapybiostatisticscancer treatmentimmunologyimmunosuppressive therapyimmunotherapy strategiescancer discoverypharmacotherapyoncologyclinical researchoncogenesmedicinal researchclinical transplantation

A Phase II Trial of Sitravatinib + Nivolumab After Progression on Immune Checkpoint Inhibitor in Patients With Metastatic Clear Cell Rcc. The Oncologist (2025)

immunologypharmacologymetastasisimmune checkpoint inhibitorspharmacotherapycancer immunotherapyphase ii trialoncologymedicinal researchcancer treatmentimmune checkpoint inhibitorexperimental medicineimmunotherapy

Assessing Pathological Response to Neoadjuvant Therapy in Renal Cell Carcinoma: A Systematic Review and Guidelines for Sampling and Reporting Standards From the International Neoadjuvant Kidney Cancer Consortium. The Lancet Oncology (2025)

medicinesurgical oncologyurologygenitourinary cancersoncologykidney cancer

1
2
3
4
5
51
10 / page

Eric Jonasch

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Clinical Cancer Genetics

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Eric Jonasch

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Monitoring and Treatment Patterns of Von Hippel-Lindau Disease-Associated Central Nervous System Hemangioblastomas. Hereditary Cancer in Clinical Practice (2026)

neurologymedicineanatomical pathologyneuropathologytreatment patternspathology

1057 Early Targeted Biologics Are Associated With Improved Clinical Outcomes in Immune-Related Myocarditis, Myositis, and Myasthenia Gravis. Regular and Young Investigator Award Abstracts (2025)

kidney researchpharmacologynephrologymolecular cancerurologypharmacotherapygenitourinary cancersoncologykidney cancermedicinal researchcancer treatmentphase ib/ii trial

48Immunotherapy Response Correlates in Metastatic Clear Cell Renal Cell Carcinoma From Circulating Cell-Free Epigenomes. The Oncologist (2025)

immunologyresponse correlatescell-free epigenomesmetastasiscancer immunosurveillanceurologycancer discoverycancer immunotherapygenitourinary cancerskidney cancercancer cellsimmunotherapy

metastasisradiation oncologysurgical oncologyurologygenitourinary cancerscancer imagingphase 2oncologykidney cancerabstract ct132cancer treatmentjama oncologypersonalized biomarker

A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned From Other Cancer Types. European Urology (2025)

kidney researchother cancer typescancer carenephrologyurologyoncologykidney cancerrenal care

A Phase II Trial of Sitravatinib + Nivolumab After Progression on Immune Checkpoint Inhibitor in Patients With Metastatic Clear Cell Rcc. The Oncologist (2025)

medicinesurgical oncologyurologygenitourinary cancersoncologykidney cancer

1
2
3
4
5
51
10 / page